ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2020, 'Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis', Journal of the American Heart Association, 9, pp. e014908, http://dx.doi.org/10.1161/JAHA.119.014908
,2020, 'Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes', JACC: Heart Failure, 8, pp. 57 - 66, http://dx.doi.org/10.1016/j.jchf.2019.08.004
,2020, 'Pilot trials in nephrology: Establishing a base for large-scale randomized trials', Journal of the American Society of Nephrology, 31, pp. 4 - 6, http://dx.doi.org/10.1681/ASN.2019111196
,2020, 'Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE', Journal of the American Society of Nephrology, 31, pp. 342 - 343, http://dx.doi.org/10.1681/asn.20203110s1342b
,2020, 'Associations Between TNFR-1, TNFR-2, and KIM-1 with Kidney and Cardiovascular Outcomes: Results from the CANVAS Trial', Journal of the American Society of Nephrology, 31, pp. 338 - 338, http://dx.doi.org/10.1681/asn.20203110s1338c
,2020, 'Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE', Journal of the American Society of Nephrology, 31, pp. b6 - b6, http://dx.doi.org/10.1681/asn.20203110s1b6a
,2020, 'Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343c
,2020, 'Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344a
,2020, 'Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343b
,2020, 'Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344b
,2020, 'Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 342 - 342, http://dx.doi.org/10.1681/asn.20203110s1342a
,2020, 'Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344c
,2020, 'Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials', Journal of the American Society of Nephrology, 31, pp. 349 - 350, http://dx.doi.org/10.1681/asn.20203110s1349c
,2020, 'Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs', Journal of the American Society of Nephrology, 31, pp. 349 - 349, http://dx.doi.org/10.1681/asn.20203110s1349b
,2020, 'Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6', Journal of the American Society of Nephrology, 31, pp. 36 - 36, http://dx.doi.org/10.1681/asn.20203110s136a
,2020, 'Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis', Journal of the American Society of Nephrology, 31, pp. 328 - 328, http://dx.doi.org/10.1681/asn.20203110s1328a
,2020, 'Risk of Hospitalization for Heart Failure (HHF) by eGFR and Urinary Albumin-to-Creatinine Ratio (UACR): Pooled Analyses from the CANVAS Program and CREDENCE', Journal of the American Society of Nephrology, 31, pp. 335 - 335, http://dx.doi.org/10.1681/asn.20203110s1335c
,2020, 'SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS', Kidney International Reports, 5, pp. S67 - S67, http://dx.doi.org/10.1016/j.ekir.2020.02.166
,2020, 'SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA – A SYSTEMATIC REVIEW AND ANALYSIS', Kidney International Reports, 5, pp. S245 - S245, http://dx.doi.org/10.1016/j.ekir.2020.02.634
,2020, 'SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES', Kidney International Reports, 5, pp. S267 - S267, http://dx.doi.org/10.1016/j.ekir.2020.02.690
,2020, 'The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial', Journal of the American Society of Nephrology, 31, pp. 228 - 229, http://dx.doi.org/10.1681/asn.20203110s1228d
,2020, 'The Effects of Allopurinol on the Progression of CKD According to Baseline Serum Urate Level: Results from Post Hoc Analyses of the CKD-FIX Trial', Journal of the American Society of Nephrology, 31, pp. 223 - 223, http://dx.doi.org/10.1681/asn.20203110s1223a
,2020, 'THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL', Journal of the American College of Cardiology, 75, pp. 674, http://dx.doi.org/10.1016/s0735-1097(20)31301-2
,2020, 'The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343a
,2019, 'Varying association of extended hours dialysis with quality of life', Clinical Journal of the American Society of Nephrology, 14, pp. 1751 - 1762, http://dx.doi.org/10.2215/CJN.06800619
,2019, 'The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program', The Lancet Rheumatology, 1, pp. e220 - e228, http://dx.doi.org/10.1016/S2665-9913(19)30078-5
,2019, 'Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review', BMJ Global Health, 4, pp. e001940, http://dx.doi.org/10.1136/bmjgh-2019-001940
,2019, 'SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 7, pp. 845 - 854, http://dx.doi.org/10.1016/S2213-8587(19)30256-6
,2019, 'The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study', Diabetologia, 62, pp. 1988 - 1997, http://dx.doi.org/10.1007/s00125-019-4948-4
,2019, 'Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering', CMAJ, 191, pp. E1128 - E1135, http://dx.doi.org/10.1503/cmaj.190047
,2019, 'Blood pressure: at what level is treatment worthwhile? (vol 42, pg 127, 2019)', AUSTRALIAN PRESCRIBER, 42, pp. 175 - 175, http://dx.doi.org/10.18773/austprescr.2019.062
,2019, 'Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program', Diabetologia, 62, pp. 1854 - 1867, http://dx.doi.org/10.1007/s00125-019-4955-5
,2019, 'P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', European Heart Journal, 40, http://dx.doi.org/10.1093/eurheartj/ehz746.0871
,2019, 'Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial', Nephrology, 24, pp. 1056 - 1063, http://dx.doi.org/10.1111/nep.13530
,2019, 'Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis', JAMA Internal Medicine, 179, pp. 1316 - 1324, http://dx.doi.org/10.1001/jamainternmed.2019.1501
,2019, 'Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply', The New England journal of medicine, 381, pp. 1089 - 1090, http://dx.doi.org/10.1056/NEJMc1909687
,2019, 'GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials', Journal of the American Society of Nephrology, 30, pp. 1735 - 1745, http://dx.doi.org/10.1681/ASN.2019010007
,2019, 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial', Circulation, 140, pp. 739 - 750, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007
,2019, 'Benefits and harms of oral anticoagulant therapy in chronic kidney disease', Annals of Internal Medicine, 171, pp. 181 - 189, http://dx.doi.org/10.7326/M19-0087
,2019, 'Blood pressure: At what level is treatment worthwhile?', Australian Prescriber, 42, pp. 127 - 130, http://dx.doi.org/10.18773/austprescr.2019.038
,2019, 'SGLT2 inhibitor lowers risk of kidney failure in type 2diabetes', Pharmaceutical Journal, 303, http://dx.doi.org/10.1211/PJ.2019.20206795
,2019, 'Is it time to REWIND the cardiorenal clock in diabetes?', The Lancet, 394, pp. 95 - 97, http://dx.doi.org/10.1016/S0140-6736(19)31267-X
,2019, 'Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study', BMC Nephrology, 20, pp. 258, http://dx.doi.org/10.1186/s12882-019-1438-3
,2019, 'Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial', Journal of Renal Nutrition, 29, pp. 276 - 284, http://dx.doi.org/10.1053/j.jrn.2018.10.009
,2019, 'Canagliflozin and renal outcomes in type 2 diabetes and nephropathy', New England Journal of Medicine, 380, pp. 2295 - 2306, http://dx.doi.org/10.1056/NEJMoa1811744
,2019, 'Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes', Clinical Journal of the American Society of Nephrology, 14, pp. 862 - 872, http://dx.doi.org/10.2215/CJN.13391118
,2019, '1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program', Diabetes, 68, http://dx.doi.org/10.2337/db19-1216-p
,2019, 'Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease', DIABETES, 68, http://dx.doi.org/10.2337/db19-432-P
,2019, 'Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program', Diabetes, 68, http://dx.doi.org/10.2337/db19-1206-p
,2019, 'Effects of canagliflozin on amputation risk in type 2 diabetes: The CANVAS Program', Diabetologia, 62, pp. 926 - 938, http://dx.doi.org/10.1007/s00125-019-4839-8
,